Share on Pinterest GLP-1s linked to higher osteoporosis risk but they may bring some benefits, too, new studies find. Image credit: SweetBunFactory/Getty Images A large percentage of Americans are ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the ...

North Carolina Poison Control is warning GLP-1 drug users to use caution when taking the medication. Poison control said last year it averaged one to two calls a day about GLP-1 drugs with 80 percent ...

Weight loss drugs like GLP-1s are rapidly reshaping how Americans think about appetite, health and food – forcing CPG brands to reconsider everything from formulation to front-of-pack messaging.

GLP-1 drugs — including Ozempic and Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according to research presented Monday at the American Academy of Orthopaedic Surgeons’ ...

Share on Pinterest Combining GLP-1 drugs with a healthy lifestyle may reduce cardiovascular risks in people with diabetes. Image Credit: Witthaya Prasongsin/Getty Images A recent study found that ...

Please provide your email address to receive an email when new articles are posted on . In patients without diabetes and with overweight, the risk for exacerbation was significantly lower in those ...

GLP-1 medications are being discussed everywhere right now: In medical offices. On social media. In celebrity interviews. But what I’m paying attention to in my therapy office is not just the ...

Walgreens is expanding its Virtual Healthcare platform with the launch of a new digital health offering, Walgreens Weight Management, which connects individuals with licensed doctors and nurse ...

State health plan overseers voted Thursday to eliminate coverage for GLP-1 drugs for obesity, capping off months of torn decision-making over how to tamp down surging health care costs while ...

State health plan overseers voted Thursday to eliminate coverage for GLP-1 drugs for obesity, capping off months of torn decision-making over how to tamp down surging health care costs while ...